Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-19 therapy
pharmaphorum
SEPTEMBER 16, 2020
Adding Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir reduces recovery time in COVID-19 patients compared to remdesivir alone, says a new trial. For now, analysis of the safety and mortality data from ACTT-2 are still ongoing, according to the president of Lilly Bio-Medicines, Patrik Jonsson.
Let's personalize your content